| Question 1: For mesh brachytherapy, the prescription point is defined as: |
| Reference: | Reference: Wenzheng Feng, Mark Rivard, Elizabeth M. Carey, Robert A. Hearn, Sujatha Pai, Ravinder Nath, Yongbok Kim, Cynthia L. Thomason, Dale E. Boyce, Hualin Zhang. “Recommendations for intraoperative mesh brachytherapy: Report of AAPM Task Group No. 222”. Med Phys. 2021; 48(11): e969-e990. |
| Choice A: | 1 cm from the source plane |
| Choice B: | 0.5 cm from source plane |
| Choice C: | 2 cm from the source plane |
| Choice D: | The target volume |
| Question 2: For a multi-source implant, what percentage of sources are required to be measured during source calibration? |
| Reference: | Reference: Butler WM, Bice WS, DeWerd LA, et al. Third-party brachytherapy source calibrations and physicist responsibilities: report of the AAPM Low Energy Brachytherapy Source Calibration Working Group. Med Phys. 2008;35(9):3860-3865. |
| Choice A: | 5% |
| Choice B: | 10% |
| Choice C: | 50% |
| Choice D: | 100% |
| Question 3: Per the NRC, which of the following is considered as a medical event? |
| Reference: | NRC 35.3045 https://www.nrc.gov/reading-rm/doc-collections/cfr/part035/part035-3045.html |
| Choice A: | Total source strength administered differing by 20% or more from the total source strength documented in the post-implantation portion of the written directive. |
| Choice B: | Sealed source(s) implanted directly into a location discontiguous from the treatment site, as documented in the post-implantation portion of the written directive. |
| Choice C: | Total source strength administered outside of the treatment site exceeding 20% of the total source strength. |
| Choice D: | Wrong radionuclide or a leaking sealed source resulting in a dose that exceeds 0.5 Sv (50 rem) to an organ or tissue. |
| Choice E: | All of the above |
| Question 4: Increasing bandwidth reduces SNR, but may be necessary to |
| Reference: | Liney GP, Moerland MA. Magnetic resonance imaging acquisition techniques for radiotherapy planning. Semin Radiat Oncol. 2014;24(3):160-168. |
| Choice A: | Reduce SAR of the sequence |
| Choice B: | Reduce chemical shift and susceptibility induced distortions |
| Choice C: | Reduce the voxel size of the acquisition |
| Choice D: | All of the above |
| Question 5: What are the advantages of a 3D over 2D sequence? |
| Reference: | Ma J, Moerland MA, Venkatesan AM, et al. Pulse sequence considerations for simulation and postimplant dosimetry of prostate brachytherapy. Brachytherapy. 2017;16(4):743-753. |
| Choice A: | Ability to acquire thinner slices |
| Choice B: | Better in-plane resolution |
| Choice C: | Less distortion along the slice direction |
| Choice D: | A and B |
| Choice E: | A and C |
| Question 6: Based on data analyzed in RetroEMBRACE, image guided adaptive brachytherapy combined with chemotherapy for cervix cancer: |
| Reference: | Sturdza A, Pötter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol 2016 Sep;120(3):428-433. |
| Choice A: | led to little to no effect on local control |
| Choice B: | led to poor local control with severe morbidity |
| Choice C: | led to excellent local control with severe morbidity |
| Choice D: | led to excellent local control with limited severe morbidity |
